Drug Patents Expiring in 2036

1. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782550

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Feb, 2036

(13 years from now)

US9782551

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Feb, 2036

(13 years from now)

US10918816

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Jun, 2036

(13 years from now)

US10569034 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

2. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782550

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Feb, 2036

(13 years from now)

US9782551

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Feb, 2036

(13 years from now)

US10918816

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Jun, 2036

(13 years from now)

US10569034 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

3. Drug name - AUSTEDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders Mar, 2036

(13 years from now)

US10959996

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders Sep, 2036

(13 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Treatment: A method of treating huntington's chorea

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
6MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

4. Drug name - BALVERSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10898482 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine Feb, 2036

(13 years from now)

Drugs and Companies using ERDAFITINIB ingredient

Treatment: Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

5. Drug name - BAQSIMI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213487 ELI LILLY AND CO Nasal powder formulation for treatment of hypoglycemia Feb, 2036

(13 years from now)

Drugs and Companies using GLUCAGON ingredient

Treatment: Treatment of severe hypoglycemia in patients with diabetes

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
3MG POWDER;NASAL Prescription

6. Drug name - BIKTARVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10548846 GILEAD SCIENCES INC Therapeutic compositions for treatment of human immunodeficiency virus Nov, 2036

(14 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE;120MG;EQ 15MG BASE TABLET;ORAL Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE TABLET;ORAL Prescription

7. Drug name - BRILINTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction Jan, 2036

(13 years from now)

Drugs and Companies using TICAGRELOR ingredient

Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription

8. Drug name - CALQUENCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9796721 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(13 years from now)

CN108349978A ASTRAZENECA (S) -4-(8-Amino - -3-(1 - (But - -2 - Alkyne Acyl) - Pyrrolidin - -2 - Yl) Imidazo [1, 5-A] Pyrazin - -1 - Yl) - N - (Pyridine - -2 - Yl) Benzamide In Solid Form And Preparation
Jul, 2036

(13 years from now)

CN108349978B ASTRAZENECA Solid Forms And Formulations Of (S) -4-(8-Amino - -3-(1 - (But - -2 - Yn-Yl) - Pyrrolidin - -2 - Yl) Imidazo [1, 5-A] Pyrazin-1-Yl) -N-(Pyridine-2-Yl) Benzamide
Jul, 2036

(13 years from now)

EP3317281A1 ASTRAZENECA Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide
Jul, 2036

(13 years from now)

EP3317281B1 ASTRAZENECA Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide
Jul, 2036

(13 years from now)

EP3613745A1 ASTRAZENECA Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide
Jul, 2036

(13 years from now)

EP3613745B1 ASTRAZENECA Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide
Jul, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10167291 ASTRAZENECA Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide Jul, 2036

(13 years from now)

Drugs and Companies using ACALABRUTINIB ingredient

Treatment: Treatment of adult patients with small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia; treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription

9. Drug name - CAROSPIR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624906 CMP DEV LLC Spironolactone aqueous compositions Oct, 2036

(14 years from now)

US10660907 CMP DEV LLC Spironolactone aqueous compositions Oct, 2036

(14 years from now)

US10888570 CMP DEV LLC Spironolactone aqueous compositions Oct, 2036

(14 years from now)

US10493083 CMP DEV LLC Spironolactone aqueous compositions Oct, 2036

(14 years from now)

US9757394 CMP DEV LLC Spironolactone aqueous formulations Oct, 2036

(14 years from now)

Drugs and Companies using SPIRONOLACTONE ingredient

Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/5ML SUSPENSION;ORAL Prescription

10. Drug name - COTELLIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10478400 GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Jun, 2036

(13 years from now)

US10590102 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Jun, 2036

(13 years from now)

CN108135854A GENENTECH INC Drug-Containing Immediate Release Tablets And A Method Of Forming A Tablet
Jun, 2036

(13 years from now)

CN108135854B GENENTECH INC Immediate Release Tablet Containing Medicine And Method For Forming Tablet
Jun, 2036

(13 years from now)

EP3316867B1 GENENTECH INC Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets
Jun, 2036

(13 years from now)

EP3316867A1 GENENTECH INC Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets
Jun, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription

11. Drug name - CYCLOPHOSPHAMIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10993952 INGENUS PHARMS LLC Stable ready to use cyclophosphamide liquid formulations Feb, 2036

(13 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/5ML (200MG/ML) SOLUTION;INTRAVENOUS Prescription
2GM/10ML (200MG/ML) SOLUTION;INTRAVENOUS Prescription
500MG/2.5ML (200MG/ML) SOLUTION;INTRAVENOUS Prescription

12. Drug name - CYSVIEW KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10556010 PHOTOCURE ASA Neoadjuvant therapy for bladder cancer Dec, 2036

(14 years from now)

Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient

Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy

Dosage: FOR SOLUTION;INTRAVESICAL

More Information on Dosage
Strength Dosage Availability
100MG/VIAL FOR SOLUTION;INTRAVESICAL Prescription

13. Drug name - DAURISMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

EP3666768B1 PFIZER Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1)
Apr, 2036

(13 years from now)

EP3286176A1 PFIZER Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Apr, 2036

(13 years from now)

EP3666768A1 PFIZER Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1)
Apr, 2036

(13 years from now)

EP3286176B1 PFIZER Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Apr, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate Apr, 2036

(13 years from now)

Drugs and Companies using GLASDEGIB MALEATE ingredient

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

14. Drug name - DELSTRIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine Nov, 2036

(14 years from now)

US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine Nov, 2036

(14 years from now)

More Information on Dosage
Strength Dosage Availability
100MG;300MG;300MG TABLET;ORAL Prescription

15. Drug name - DEXMEDETOMIDINE HYDROCHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717796 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container Apr, 2036

(13 years from now)

US9649296 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container Apr, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/10ML (EQ 100MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) SOLUTION;INTRAVENOUS Prescription

16. Drug name - DUOBRII

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10251895 BAUSCH Topical compositions and methods for treating psoriasis Jun, 2036

(13 years from now)

US10426787 BAUSCH Topical compositions and methods for treating psoriasis Jun, 2036

(13 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.01%;0.045% LOTION;TOPICAL Prescription

17. Drug name - ELYXYB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376527 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US9572819 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US9795620 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US9949990 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US10799517 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US10722456 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

Drugs and Companies using CELECOXIB ingredient

Treatment: Acute treatment of migraine with or without aura in adults

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/ML SOLUTION;ORAL Prescription

18. Drug name - ENTRESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11058667 NOVARTIS PHARMS CORP Sacubitril-valsartan dosage regimen for treating heart failure May, 2036

(13 years from now)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Treatment: Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually recommended starting dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
24MG;26MG TABLET;ORAL Prescription
49MG;51MG TABLET;ORAL Prescription
97MG;103MG TABLET;ORAL Prescription

19. Drug name - EPANED

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9669008 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US10154987 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US9808442 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US10039745 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US11173141 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US11141405 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US11040023 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US10772868 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

US10786482 AZURITY Enalapril formulations Mar, 2036

(13 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Treatment: Treatment of hypertension; method of treating left ventricular dysfunction; method of treating hypertension; method of treatment of heart failure; treatment of heart failure; Method of treatment of heart failure; treatment of heart failure; method of treating hypertension; method of treating left ventricular dysfunction; treatment of hypertension

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
1MG/ML SOLUTION;ORAL Prescription

20. Drug name - ESOMEPRAZOLE MAGNESIUM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835488 DEXCEL PHARMA Stable orally disintegrating pharmaceutical compositions Dec, 2036

(14 years from now)

US10076494 DEXCEL PHARMA Stable orally disintegrating pharmaceutical compositions Dec, 2036

(14 years from now)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

21. Drug name - EXEM FOAM KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9849199 GISKIT Composition and method for medical imaging of body cavities Feb, 2036

(13 years from now)

Drugs and Companies using AIR POLYMER-TYPE A ingredient

Treatment: NA

Dosage: FOAM;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
10ML FOAM;INTRAUTERINE Prescription

22. Drug name - EZALLOR SPRINKLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543 SUN PHARM Stable multiparticulate pharmaceutical composition of rosuvastatin Feb, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 40MG BASE CAPSULE;ORAL Prescription

23. Drug name - FINTEPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10947183 ZOGENIX INC Fenfluramine compositions and methods of preparing the same
Dec, 2036

(14 years from now)

CN108883399A ZOGENIX INC Fenfluramine Composition And Preparation Method Thereof
Dec, 2036

(14 years from now)

CN108883399B ZOGENIX INC Faffluramine Composition And Preparation Method Thereof
Dec, 2036

(14 years from now)

EP3393655A4 ZOGENIX INC Fenfluramine Compositions And Methods Of Preparing The Same
Dec, 2036

(14 years from now)

EP3393655A1 ZOGENIX INC Fenfluramine Compositions And Methods Of Preparing The Same
Dec, 2036

(14 years from now)

EP3393655B1 ZOGENIX INC Fenfluramine Compositions And Methods Of Preparing The Same
Dec, 2036

(14 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.2MG BASE/ML SOLUTION;ORAL Prescription

24. Drug name - FYARRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10705070 AADI Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug Mar, 2036

(13 years from now)

US10973806 AADI Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin Jun, 2036

(13 years from now)

Drugs and Companies using SIROLIMUS ingredient

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

25. Drug name - GAVRETO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10030005 GENENTECH INC Inhibitors of RET
Nov, 2036

(14 years from now)

CN108473468B GENENTECH INC Inhibitors Of Ret
Nov, 2036

(14 years from now)

CN108473468A GENENTECH INC Inhibitors Of Ret
Nov, 2036

(14 years from now)

Drugs and Companies using PRALSETINIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription

26. Drug name - GENOSYL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213572 VERO BIOTECH Nitrogen dioxide storage cassette Feb, 2036

(13 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
800PPM GAS;INHALATION Prescription

27. Drug name - GLOPERBA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9907751 ROMEG Composition and method of use of colchicine oral liquid Nov, 2036

(14 years from now)

US10383820 ROMEG Colchicine drug-to-drug interactions Nov, 2036

(14 years from now)

US10383821 ROMEG Colchicine drug-to-drug interactions Nov, 2036

(14 years from now)

Drugs and Companies using COLCHICINE ingredient

Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.6MG/5ML SOLUTION;ORAL Prescription

28. Drug name - GVOKE HYPOPEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649364 XERIS Methods for producing stable therapeutic formulations in aprotic polar solvents Apr, 2036

(13 years from now)

Drugs and Companies using GLUCAGON ingredient

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.5MG/0.1ML (0.5MG/0.1ML) SOLUTION;SUBCUTANEOUS Prescription
1MG/0.2ML (1MG/0.2ML) SOLUTION;SUBCUTANEOUS Prescription

29. Drug name - IBRANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065250 PFIZER Solid dosage forms of palbociclib May, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
125MG TABLET;ORAL Prescription

30. Drug name - IMBRUVICA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828259 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar, 2036

(13 years from now)

US10010507 PHARMACYCLICS INC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Mar, 2036

(13 years from now)

US10213386 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar, 2036

(13 years from now)

US9655857 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar, 2036

(13 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
140MG TABLET;ORAL Prescription
280MG TABLET;ORAL Prescription
420MG TABLET;ORAL Prescription
560MG TABLET;ORAL Prescription

31. Drug name - INGREZZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10065952 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(14 years from now)

US10844058 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(14 years from now)

US10851103 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(14 years from now)

US10851104 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(14 years from now)

US10919892 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(14 years from now)

US10906902 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(14 years from now)

US10906903 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(14 years from now)

EP3368534A1 NEUROCRINE Valbenazine Ditosylate And Polymorphs Thereof
Oct, 2036

(14 years from now)

EP3368534B1 NEUROCRINE Valbenazine Ditosylate And Polymorphs Thereof
Oct, 2036

(14 years from now)

EP3394057B1 NEUROCRINE Synthetic Method For Preparation Of (S)-(2R,3R,11Br)-3-Isobutyl-9,10-Dimethoxy-2,3,4,6,7,11B-Hexahydro-1H-Pyrido[2,1,-A]Lsoquinolin-2-Yl 2-Amino-3-Methylbutanoate Di(4-Methylbenzenesulfonate)
Dec, 2036

(14 years from now)

EP3394057A1 NEUROCRINE Synthetic Method For Preparation Of (S)-(2R,3R,11Br)-3-Isobutyl-9,10-Dimethoxy-2,3,4,6,7,11B-Hexahydro-1H-Pyrido[2,1,-A]Lsoquinolin-2-Yl 2-Amino-3-Methylbutanoate Di(4-Methylbenzenesulfonate)
Dec, 2036

(14 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription
EQ 60MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

32. Drug name - INLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869924 PF PRISM CV PD-L1 antagonist combination treatments Nov, 2036

(14 years from now)

Drugs and Companies using AXITINIB ingredient

Treatment: Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

33. Drug name - INOMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770570 MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery May, 2036

(13 years from now)

US9770570

(Pediatric)

MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery Nov, 2036

(14 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
100PPM GAS;INHALATION Discontinued
800PPM GAS;INHALATION Prescription

34. Drug name - INVEGA HAFYERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters Apr, 2036

(13 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; reinitiation of schizophrenia treatment following a missed dose 4-9 months ago

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
1.092GM/3.5ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
1.560GM/5ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
273MG/0.875ML (273MG/0.875ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
410MG/1.315ML (311.79MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
546MG/1.75ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
819MG/2.625ML (312MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

35. Drug name - KISQALI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799506 NOVARTIS Ribociclib tablet Apr, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

36. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799506 NOVARTIS Ribociclib tablet Apr, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
2.5MG;EQ 200MG BASE TABLET;ORAL Prescription

37. Drug name - KORLYM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943526 CORCEPT THERAP Optimizing mifepristone levels for cushing's patients Apr, 2036

(13 years from now)

US10166242 CORCEPT THERAP Optimizing mifepristone levels for Cushing's patients Apr, 2036

(13 years from now)

US10166243 CORCEPT THERAP Optimizing mifepristone levels for cushing'S patients Apr, 2036

(13 years from now)

US10660904 CORCEPT THERAP Optimizing mifepristone levels for cushing's patients Apr, 2036

(13 years from now)

US10006924 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent cushing's syndrome Aug, 2036

(13 years from now)

US10495650 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent Cushing's syndrome Aug, 2036

(13 years from now)

US9829495 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent Cushing's syndrome Aug, 2036

(13 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

38. Drug name - KYNMOBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449146 SUNOVION PHARMS INC Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa Apr, 2036

(13 years from now)

US10959943 SUNOVION PHARMS INC Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa Apr, 2036

(13 years from now)

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
10MG FILM;SUBLINGUAL Prescription
15MG FILM;SUBLINGUAL Prescription
20MG FILM;SUBLINGUAL Prescription
25MG FILM;SUBLINGUAL Prescription
30MG FILM;SUBLINGUAL Prescription

39. Drug name - LANSOPRAZOLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077055 DEXCEL PHARMA Orally disintegrating compositions Apr, 2036

(13 years from now)

Drugs and Companies using LANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Over the counter

40. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder Aug, 2036

(13 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

41. Drug name - LEVOTHYROXINE SODIUM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154498 CUSTOPHARM INC Stabilized liquid formulation of levothyroxine Jul, 2036

(13 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MCG/ML SOLUTION;INTRAVENOUS Prescription

42. Drug name - LEVOTHYROXINE SODIUM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398669 FRESENIUS KABI USA Levothyroxine liquid formulations Dec, 2036

(14 years from now)

US9782376 FRESENIUS KABI USA Levothyroxine liquid formulations Dec, 2036

(14 years from now)

US11135190 FRESENIUS KABI USA Levothyroxine liquid formulations Dec, 2036

(14 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MCG/5ML (20MCG/ML) SOLUTION;INTRAVENOUS Prescription
200MCG/5ML (40MCG/ML) SOLUTION;INTRAVENOUS Prescription
500MCG/5ML (100MCG/ML) SOLUTION;INTRAVENOUS Prescription

43. Drug name - LEXETTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020407 MAYNE PHARMA Corticosteroid containing foam compositions and method of manufacture thereof Nov, 2036

(14 years from now)

US10857159 MAYNE PHARMA Halobetasol foam composition and method of use thereof Nov, 2036

(14 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.05% AEROSOL, FOAM;TOPICAL Prescription

44. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688518 SUNOVION RESP Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator Nov, 2036

(14 years from now)

US10744277 SUNOVION RESP Aerosol delivery device and method of operating the aerosol delivery device Dec, 2036

(14 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: A method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

45. Drug name - LORBRENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(13 years from now)

EP3328867A1 PFIZER Crystalline Form Of Lorlatinib Free Base
Jul, 2036

(13 years from now)

EP3328867B1 PFIZER Crystalline Form Of Lorlatinib Free Base
Jul, 2036

(13 years from now)

EP3328867B9 PFIZER Crystalline Form Of Lorlatinib Free Base
Jul, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376 PFIZER Crystalline form of lorlatinib free base Jul, 2036

(13 years from now)

Drugs and Companies using LORLATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

46. Drug name - LOTEMAX SM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596107 BAUSCH AND LOMB INC Ophthalmic suspension composition Dec, 2036

(14 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Treatment: Treatment of post-operative inflammation and pain following ocular surgery

Dosage: GEL;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.38% GEL;OPHTHALMIC Prescription

47. Drug name - MAKENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9844558 COVIS Methods of reducing risk of preterm birth May, 2036

(13 years from now)

US11154562 COVIS Methods of reducing risk of preterm birth May, 2036

(13 years from now)

US10471075 COVIS Methods of reducing risk of preterm birth May, 2036

(13 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1250MG/5ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
250MG/ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
275MG/1.1ML (250MG/ML) SOLUTION;SUBCUTANEOUS Prescription

48. Drug name - MAVYRET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11246866 ABBVIE INC Solid pharmaceutical compositions for treating HCV Jun, 2036

(13 years from now)

US11246866

(Pediatric)

ABBVIE INC Solid pharmaceutical compositions for treating HCV Dec, 2036

(14 years from now)

More Information on Dosage
Strength Dosage Availability
100MG;40MG TABLET;ORAL Prescription

49. Drug name - MINOLIRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103517 EPI HLTH Pharmaceutical compositions for minocycline Apr, 2036

(13 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 105MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 135MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

50. Drug name - MYCAPSSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238709 AMRYT Method of treating diseases Feb, 2036

(13 years from now)

US11052126 AMRYT Method of treating diseases Feb, 2036

(13 years from now)

US10695397 AMRYT Method of treating diseases Feb, 2036

(13 years from now)

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

51. Drug name - MYRBETRIQ GRANULES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10058536 APGDI Pharmaceutical composition containing mirabegron Mar, 2036

(13 years from now)

US10058536

(Pediatric)

APGDI Pharmaceutical composition containing mirabegron Oct, 2036

(14 years from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

52. Drug name - NEXLIZET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912751 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease Mar, 2036

(13 years from now)

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

Treatment: A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
180MG;10MG TABLET;ORAL Prescription

53. Drug name - NUBEQA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(13 years from now)

US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(13 years from now)

EP3250554A1 BAYER HEALTHCARE A Carboxamide Derivative And Its Diastereomers In Stable Crystalline Form
Jan, 2036

(13 years from now)

EP3250554B1 BAYER HEALTHCARE A Carboxamide Derivative And Its Diastereomers In Stable Crystalline Form
Jan, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form Jan, 2036

(13 years from now)

Drugs and Companies using DAROLUTAMIDE ingredient

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

54. Drug name - OCALIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10758549 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use Apr, 2036

(13 years from now)

US10751349 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use Apr, 2036

(13 years from now)

US10052337 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use Apr, 2036

(13 years from now)

Drugs and Companies using OBETICHOLIC ACID ingredient

Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as monotherapy in adults unable to tolerate udca

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

55. Drug name - OMEPRAZOLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076494 DEXCEL PHARMA Stable orally disintegrating pharmaceutical compositions Dec, 2036

(14 years from now)

US10835488 DEXCEL PHARMA Stable orally disintegrating pharmaceutical compositions Dec, 2036

(14 years from now)

Drugs and Companies using OMEPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Over the counter

56. Drug name - ONIVYDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456360 IPSEN INC Stabilizing camptothecin pharmaceutical compositions Oct, 2036

(14 years from now)

US10993914 IPSEN INC Stabilizing camptothecin pharmaceutical compositions Oct, 2036

(14 years from now)

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) INJECTABLE, LIPOSOMAL;INTRAVENOUS Prescription

57. Drug name - ORGOVYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350170 MYOVANT SCIENCES Solid preparation Feb, 2036

(13 years from now)

Drugs and Companies using RELUGOLIX ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
120MG TABLET;ORAL Prescription

58. Drug name - ORILISSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537572 ABBVIE INC Methods of administering elagolix Sep, 2036

(13 years from now)

US10682351 ABBVIE INC Methods of administering elagolix Sep, 2036

(13 years from now)

Drugs and Companies using ELAGOLIX SODIUM ingredient

Treatment: Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Prescription

59. Drug name - ORTIKOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10172802 SUN PHARM INDS INC Oral pharmaceutical dosage forms of budesonide Sep, 2036

(13 years from now)

US9707182 SUN PHARM INDS INC Oral pharmaceutical dosage forms of budesonide Sep, 2036

(13 years from now)

Drugs and Companies using BUDESONIDE ingredient

Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
6MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
9MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

60. Drug name - OXBRYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020382 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde Dec, 2036

(14 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: Treating sickle cell disease by administering 1500 mg of voxelotor orally once daily; increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET, FOR SUSPENSION;ORAL Prescription

61. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2036

(13 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

62. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143665 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10905662 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10548859 HORIZON PHARMA USA Methods for storing Cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10328037 HORIZON PHARMA USA Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: GRANULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription
EQ 300MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription

63. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143665 HORIZON Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10328037 HORIZON Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10548859 HORIZON Methods for storing Cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10905662 HORIZON Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

64. Drug name - RINVOQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10981923 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

US9951080 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

US11186584 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10995095 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10597400 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10730883 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US9963459 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof Oct, 2036

(14 years from now)

US10981924 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10519164 ABBVIE INC Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10344036 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US11198697 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

US10550126 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Oct, 2036

(14 years from now)

Drugs and Companies using UPADACITINIB ingredient

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription

65. Drug name - TASCENSO ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10925829 HANDA Stable solid fingolimod dosage forms Jan, 2036

(13 years from now)

US10555902 HANDA Stable fingolimod dosage forms Jan, 2036

(13 years from now)

US9925138 HANDA Stable solid fingolimod dosage forms Jan, 2036

(13 years from now)

Drugs and Companies using FINGOLIMOD LAURYL SULFATE ingredient

Treatment: Treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Prescription

66. Drug name - TURALIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10730876 DAIICHI SANKYO INC Synthesis of a compound that modulates kinases
May, 2036

(13 years from now)

US9802932 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

CN107548394B DAIICHI SANKYO INC A Solid Form Of The Compound For Modulating Kinase
May, 2036

(13 years from now)

CN107548394A DAIICHI SANKYO INC Solid Forms Of The Kinase Modulating Compound
May, 2036

(13 years from now)

EP3581573A1 DAIICHI SANKYO INC Synthesis Of A Compound That Modulates Kinases
May, 2036

(13 years from now)

EP3292122B1 DAIICHI SANKYO INC Synthesis Of 1H-Pyrrolo[2,3-B]Pyridin Derivatives That Modulate Kinases
May, 2036

(13 years from now)

EP3292123B1 DAIICHI SANKYO INC Solid Forms Of A Compound Modulating Kinases
May, 2036

(13 years from now)

EP3581573B1 DAIICHI SANKYO INC Synthesis Of A Compound That Modulates Kinases
May, 2036

(13 years from now)

EP3292123A1 DAIICHI SANKYO INC Solid Forms Of A Compound Modulating Kinases
May, 2036

(13 years from now)

EP3292122A1 DAIICHI SANKYO INC Synthesis Of 1H-Pyrrolo[2,3-B]Pyridin Derivatives That Modulate Kinases
May, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189833 DAIICHI SANKYO INC Solid forms of a compound modulating kinases May, 2036

(13 years from now)

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE CAPSULE;ORAL Prescription

67. Drug name - UPTRAVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821108 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide Dec, 2036

(14 years from now)

US10828298 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide Dec, 2036

(14 years from now)

Drugs and Companies using SELEXIPAG ingredient

Treatment: Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.2MG TABLET;ORAL Prescription
0.4MG TABLET;ORAL Prescription
0.6MG TABLET;ORAL Prescription
0.8MG TABLET;ORAL Prescription
1MG TABLET;ORAL Prescription
1.2MG TABLET;ORAL Prescription
1.4MG TABLET;ORAL Prescription
1.6MG TABLET;ORAL Prescription

68. Drug name - VEKLURY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections Sep, 2036

(13 years from now)

US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections Sep, 2036

(13 years from now)

Drugs and Companies using REMDESIVIR ingredient

Treatment: Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg)

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription
100MG/20ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

69. Drug name - VITRAKVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10799505 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE;ORAL Prescription
EQ 100MG BASE CAPSULE;ORAL Prescription

70. Drug name - VITRAKVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10799505 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/ML SOLUTION;ORAL Prescription

71. Drug name - VOXZOGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9907834 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia Aug, 2036

(13 years from now)

US10646550 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia Aug, 2036

(13 years from now)

Drugs and Companies using VOSORITIDE ingredient

Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/VIAL POWDER;SUBCUTANEOUS Prescription
0.56MG/VIAL POWDER;SUBCUTANEOUS Prescription
1.2MG/VIAL POWDER;SUBCUTANEOUS Prescription

72. Drug name - XACIATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129896 DARE Topical formulations and treatments Sep, 2036

(13 years from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation

Dosage: GEL;VAGINAL

More Information on Dosage
Strength Dosage Availability
EQ 2% BASE GEL;VAGINAL Prescription

73. Drug name - XOFLUZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10392406 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(13 years from now)

CN113004304B GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Apr, 2036

(13 years from now)

CN112940010B GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Apr, 2036

(13 years from now)

CN112940010A GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Apr, 2036

(13 years from now)

CN113004304A GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Apr, 2036

(13 years from now)

IN346800B GENENTECH INC Substituted Polycyclic Pyridone Derivative And Prodrug Thereof
Apr, 2036

(13 years from now)

IN201747041390A GENENTECH INC Substituted Polycyclic Pyridone Derivative And Prodrug Thereof
Apr, 2036

(13 years from now)

EP3428170A1 GENENTECH INC Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof
Apr, 2036

(13 years from now)

EP3428170B1 GENENTECH INC Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof
Apr, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10633397 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof Apr, 2036

(13 years from now)

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

Treatment: Method for post-exposure prophylaxis of influenza; method for treating influenza

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription

74. Drug name - XOSPATA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786500 ASTELLAS Stable pharmaceutical composition for oral administration Jul, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription

75. Drug name - XTAMPZA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646485 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations Sep, 2036

(13 years from now)

US9968598 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations Sep, 2036

(13 years from now)

US9737530 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations Sep, 2036

(13 years from now)

US10188644 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations Sep, 2036

(13 years from now)

Drugs and Companies using OXYCODONE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
9MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
13.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
18MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
27MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
36MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

76. Drug name - XYOSTED (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9950125 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions Sep, 2036

(13 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
50MG/0.5ML (50MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
75MG/0.5ML (75MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
100MG/0.5ML (100MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

77. Drug name - ZEMBRACE SYMTOUCH

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537554 UPSHER SMITH LABS Pharmaceutical composition for treating migraine Jan, 2036

(13 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Treatment of migraine

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

78. Drug name - ZURAGARD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9844654 ZUREX PHARMA Medical skin applicator apparatus Apr, 2036

(13 years from now)

Drugs and Companies using ISOPROPYL ALCOHOL ingredient

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
70% SOLUTION;TOPICAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.